STOCK TITAN
  1. Home
  2. Sec-filings
  3. QNCX
  4. [8-K] Quince Therapeutics, Inc. Reports Material Event

[8-K] Quince Therapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock QNCX logo
Quince

NASDAQ:QNCX

QNCX Rankings

#7367 Ranked by Market Cap
N/A Ranked by Dividends

QNCX Latest News

Jul 16, 2025
Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Jul 10, 2025
Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board
Jun 25, 2025
Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference
Jun 18, 2025
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities
Jun 12, 2025
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

QNCX Latest SEC Filings

Jul 1, 2025
[D] Quince Therapeutics, Inc. SEC Filing
Jun 23, 2025
[Form 4] Quince Therapeutics, Inc. Insider Trading Activity
Jun 23, 2025
[Form 4] Quince Therapeutics, Inc. Insider Trading Activity
Jun 23, 2025
[Form 4] Quince Therapeutics, Inc. Insider Trading Activity

QNCX Stock Data

89.16M
39.50M
13.52%
23.46%
5.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO